Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Assets (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Non-Current Assets for 12 consecutive years, with $3.6 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets changed N/A year-over-year to $3.6 million; the TTM value through Mar 2026 reached $14.1 million, up 810.1%, while the annual FY2025 figure was $3.6 million, N/A changed from the prior year.
  • Non-Current Assets hit $3.6 million in Q1 2026 for Crescent Biopharma, down from $3.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.0 million in Q1 2022 and bottomed at $52320.0 in Q3 2024.
  • Average Non-Current Assets over 5 years is $2.1 million, with a median of $1.5 million recorded in 2023.
  • Year-over-year, Non-Current Assets tumbled 95.61% in 2024 and then soared 6983.33% in 2025.
  • Crescent Biopharma's Non-Current Assets stood at $1.1 million in 2022, then soared by 39.22% to $1.5 million in 2023, then tumbled by 96.57% to $52320.0 in 2024, then soared by 6853.36% to $3.6 million in 2025, then fell by 1.95% to $3.6 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $3.6 million, $3.6 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.